The Claim
In adults with type 2 diabetes and chronic kidney disease, the concomitant use of mineralocorticoid receptor antagonists does not meaningfully alter the safety profile of semaglutide, including no significant increase in the risk of hyperkalemia.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults with type 2 diabetes and chronic kidney disease, taking semaglutide along with mineralocorticoid receptor antagonists does not lead to a meaningful increase in the risk of high blood potassium levels.
See the scientific wording
In adults with type 2 diabetes and chronic kidney disease, the safety profile of semaglutide is not meaningfully altered by concomitant use of mineralocorticoid receptor antagonists, including no significant increase in hyperkalemia risk.
Semaglutide does not interfere with how the kidneys remove potassium from the blood, even when drugs that slow potassium removal are also present. The kidneys continue to excrete potassium normally, so blood potassium levels stay within safe limits.
What the research says
1 studyThis study found that people with diabetes and kidney disease who took semaglutide along with potassium-regulating drugs didn’t have more high potassium problems than those who took semaglutide alone. So, adding semaglutide doesn’t seem to make high potassium levels worse.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.